Luminex Posts 12 Percent Q2 Revenue Growth; Stock Sinks | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its second-quarter revenues grew 12 percent year over year, driven by a 24 percent spike in its assay revenue.

The Austin, Texas-based molecular diagnostics firm reported total revenues of $54.3 million for the three months ended June 30, compared to $48.3 million for the second quarter of 2012. It inched past analysts' consensus estimate for revenues of $54.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.